Stocklytics Platform
Asset logo for symbol FDMT
4D Molecular Therapeutics
FDMT54
$8.09arrow_drop_up1.12%$0.08
Asset logo for symbol FDMT
FDMT54

$8.09

arrow_drop_up1.12%

Income Statement (FDMT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
EBIT-$42.45M-$38.13M-$36.65M-$13.97M-$33.56M
EBITDA-$40.83M-$36.54M-$35.13M-$12.57M-$32.13M
gross Profit-$1.61M-$1.56M-$4.25M$18.80M-$1.18M
NET Income-$34.95M-$32.40M-$32.28M-$10.25M-$29.61M
total Revenue$5,000.00$28.00K-$19.00K$20.20M$239.00K

Balance Sheet (FDMT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
cash Equivalents-----
net Debt-$175.40M-$261.42M-$234.43M-$260.52M-$294.71M
stockholders Equity$588.34M$600.56M$307.82M$329.93M-$372.78M
total Assets$620.11M$629.88M$339.89M$361.61M$352.50M
total Debt$13.65M$14.17M$14.67M$15.15M$15.63M
total Liabilities$31.77M$29.32M$32.06M$31.67M$725.29M

Cash Flow (FDMT)

itemJun 2024Mar 2024Dec 2023Sep 2023Jun 2023
financing Cash Flow$17.24M$318.83M$4.76M$10.55M$130.51M
free Cash Flow-$30.59M-$29.79M-$25.19M-$1.57M-$22.87M
investing Cash Flow----$49.28M
operating Cash Flow-$30.24M-$29.08M-$24.65M-$1.17M-$22.06M

4D Molecular Therapeutics (FDMT) Financials

The income statement of 4D Molecular Therapeutics, Inc. (FDMT) provides a snapshot of the company's financial performance over a specific period. It outlines the revenue generated by the company and deducts the cost of goods sold to determine the gross profit. Operating expenses, such as research and development costs and general administrative expenses, are then subtracted from the gross profit to arrive at the earnings before interest and taxes (EBIT). This figure reflects the company's profitability before considering interest expenses and taxes. EBITDA, or earnings before interest, taxes, depreciation, and amortization, is a similar measure that adds back depreciation and amortization expenses to the EBIT.
The gross profit of 4D Molecular Therapeutics, Inc. (FDMT) is the difference between its total revenue and the cost of goods sold. It represents the amount of money the company earns from its core operations after accounting for direct costs. Gross profit is an essential metric to assess a company's profitability and efficiency in its production processes. Net income from stockholders, on the other hand, is the profit attributable to the company's equity holders after deducting taxes, interest, and other expenses. It is an indicator of the company's profitability from the perspective of its investors.
add 4D Molecular Therapeutics to watchlist

Keep an eye on 4D Molecular Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level